Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD refers prostate supplement ad to FTC, FDA

This article was originally published in The Tan Sheet

Executive Summary

The National Advertising Division refers advertising for the prostate health supplement Prostalex Plus to the Federal Trade Commission and FDA after the marketer, Herbal Groups, declined to participate in the Better Business Bureaus' review process. NAD requested substantiation for claims that the "all-natural supplement" would "solve your urination problems, improve prostate function" and combat the natural growth of the prostate. It also was concerned that "the Prostate Health Blog" linked on the advertiser's Web site is not independently written as it appears, but is advertising. The firm submitted a study on Prostalex, but declined to participate in the review process, NAD said in a May 5 release. The watchdog group, which rarely refers advertisers to enforcement agencies, has referred six companies to regulators this year (1"The Tan Sheet" Feb. 16, 2009, p. 19)

Related Content

Topics

UsernamePublicRestriction

Register

PS102898

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel